Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.20 – $8.85
100% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.49B | $5.10B | $5.34B | $4.93B | $6.06B | $6.59B | $7.21B | $7.52B |
| Cost of revenue | $2.44B | $2.76B | $3.08B | $2.97B | $3.83B | $4.10B | $4.42B | $4.66B |
| Gross profit | $2.05B | $2.34B | $2.26B | $1.96B | $2.21B | $2.49B | $2.79B | $2.86B |
| Gross margin | 45.7% | 45.9% | 42.2% | 39.8% | 36.5% | 37.8% | 38.7% | 38.0% |
| R&D | $240.7M | $276.0M | $294.2M | $354.9M | $361.1M | $395.3M | $384.0M | $425.9M |
| Operating income | $994.1M | $1.13B | $996.1M | $595.1M | $782.4M | $799.4M | $1.19B | $1.24B |
| EBITDA | $1.22B | $1.44B | $1.30B | $922.3M | $1.21B | $1.18B | $1.48B | $1.64B |
| Net income | $596.6M | $625.1M | $618.5M | $188.7M | $208.3M | $59.3M | $156.9M | $401.7M |
| Net margin | 13.3% | 12.3% | 11.6% | 3.8% | 3.4% | 0.9% | 2.2% | 5.3% |
| EPS (diluted) | 0.87 | 0.91 | 0.90 | 0.28 | 0.31 | 0.09 | 0.22 | 0.59 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7.7B | $0.82 | $0.79–$0.85 | 1 |
| 2027 | $8.1B | $1.06 | $1.02–$1.09 | 1 |
| 2028 | $8.6B | $1.38 | $1.31–$1.41 | 1 |
| 2029 | $9.2B | $1.54 | $1.47–$1.58 | 1 |
Forward consensus · source: Financial Modeling Prep
GRIFOLS SA B SHS NEW
No one on the platform currently holds GIFOF.
No tracked institution reports a position in GIFOF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-01 | $0.0101 | 2026-07-02 |
| 2026-07-01 | $0.0824 | 2026-07-02 |
| 2025-08-12 | $0.1500 | 2025-08-13 |
| Execution date | Ratio |
|---|---|
| 2016-01-29 | 2-for-1 |
| 2012-12-11 | 21-for-20 |
No one on the platform has traded GIFOF yet.
| $6.3B |
| — |
| OPHLYOno Pharmaceutical Co., Ltd. | $4.85 | -1.02% | $6.8B | — |
| RCDTFRecordati S.p.A. | $58.00 | +0.00% | $11.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 31.9× earnings vs its 35.6× historical median P/E.
Fair value ≈ $9.89 · price $8.85 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.